Abstract
The upregulated miR-17-3p is associated with fetal hemoglobin (HbF) in patients with $\beta$-thalassemia. Although miR-17-3p does not significantly affect erythropoiesis, it promotes $\gamma$-globin expression by directly targeting BCL11A, a known repressor. These findings suggest that miR-17-3p may serve as a promising therapeutic target for the treatment of $\beta$-thalassemia.
Introduction
$\beta$-thalassemia is a hereditary blood disorder characterized by impaired $\beta$-globin chain production, leading to severe anemia. A primary therapeutic strategy involves the reactivation of fetal hemoglobin (HbF), which consists of $\alpha$-globin and $\gamma$-globin. While transcription factors like BCL11A are known to repress $\gamma$-globin expression postnatally, the microRNA (miRNA) regulators controlling these factors remain under investigation. This study explores the role of miR-17-3p in modulating BCL11A and inducing HbF production.
Methods
The study utilized a clinical cohort of 17 $\beta$-thalassemia patients and 17 healthy controls to correlate miR-17-3p levels with clinical markers. Molecular validation involved dual-luciferase reporter assays in HEK-293T cells to confirm binding between miR-17-3p and the 3’-UTR of BCL11A. Functional assays were conducted in K562 erythroleukemia cells using miR-17-3p mimics and inhibitors to assess effects on BCL11A and $\gamma$-globin protein levels, alongside phenotyping for cell proliferation and apoptosis.
Results
Clinical Correlation and Upregulation
Clinical analysis demonstrated that miR-17-3p expression was approximately 3.2-fold higher in $\beta$-thalassemia patients compared to healthy controls ($3.54 \pm 2.31$ vs. $1.11 \pm 1.03$, $P < 0.001$). Notably, miR-17-3p levels showed a strong positive correlation with HbF levels ($r = 0.686$) and were significantly elevated in patients with high HbF concentrations.
Molecular Mechanism
Bioinformatics and luciferase assays confirmed that miR-17-3p directly targets the 3’-UTR of BCL11A. In K562 cells, miR-17-3p mimics reduced BCL11A protein levels while simultaneously increasing $\gamma$-globin expression. Importantly, miR-17-3p overexpression did not negatively impact cell proliferation, cycle progression, or apoptosis, suggesting high specificity for hemoglobin modulation without disrupting general hematopoiesis.
Discussion
miR-17-3p acts as a "repressor of the repressor" by silencing BCL11A, thereby unlocking $\gamma$-globin production. With an Area Under the Curve (AUC) of 0.8824, miR-17-3p also shows potential as a non-invasive biomarker for disease monitoring. While these results are promising, future work must validate these mechanisms in primary human CD34+ hematopoietic stem cells and address the challenges of targeted miRNA delivery to bone marrow.
Summary updated